COSTANTINO, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.589
EU - Europa 9.495
AS - Asia 9.306
SA - Sud America 1.274
AF - Africa 244
Continente sconosciuto - Info sul continente non disponibili 239
OC - Oceania 31
Totale 47.178
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.073
GB - Regno Unito 3.131
SG - Singapore 2.665
CN - Cina 2.590
IT - Italia 1.896
SE - Svezia 1.049
VN - Vietnam 1.027
HK - Hong Kong 1.014
BR - Brasile 994
DE - Germania 819
UA - Ucraina 499
RU - Federazione Russa 468
BD - Bangladesh 451
FI - Finlandia 424
FR - Francia 410
TR - Turchia 393
KR - Corea 297
IN - India 255
CA - Canada 254
BG - Bulgaria 178
NL - Olanda 130
AR - Argentina 89
JP - Giappone 87
MX - Messico 87
ID - Indonesia 82
IQ - Iraq 77
PL - Polonia 67
ZA - Sudafrica 67
ES - Italia 64
IE - Irlanda 60
BE - Belgio 51
PK - Pakistan 49
EC - Ecuador 48
CH - Svizzera 39
AE - Emirati Arabi Uniti 38
CL - Cile 35
MA - Marocco 31
RO - Romania 30
CO - Colombia 29
PH - Filippine 29
LT - Lituania 28
AU - Australia 27
CR - Costa Rica 25
PY - Paraguay 25
EG - Egitto 24
VE - Venezuela 24
IL - Israele 22
AT - Austria 21
IR - Iran 21
JM - Giamaica 21
KE - Kenya 21
PT - Portogallo 21
SA - Arabia Saudita 21
TW - Taiwan 21
GT - Guatemala 20
DZ - Algeria 19
JO - Giordania 19
SV - El Salvador 19
MY - Malesia 18
AZ - Azerbaigian 17
NI - Nicaragua 17
SC - Seychelles 17
HN - Honduras 16
MD - Moldavia 15
PE - Perù 15
TH - Thailandia 15
UZ - Uzbekistan 15
CZ - Repubblica Ceca 14
NP - Nepal 14
TN - Tunisia 13
TT - Trinidad e Tobago 13
PR - Porto Rico 12
BY - Bielorussia 11
EU - Europa 11
DK - Danimarca 10
UY - Uruguay 10
GR - Grecia 9
SN - Senegal 9
CW - ???statistics.table.value.countryCode.CW??? 8
EE - Estonia 8
KZ - Kazakistan 8
NO - Norvegia 8
DO - Repubblica Dominicana 7
LB - Libano 7
LK - Sri Lanka 7
RS - Serbia 7
AO - Angola 6
BB - Barbados 6
BH - Bahrain 6
CI - Costa d'Avorio 6
ET - Etiopia 6
QA - Qatar 6
KG - Kirghizistan 5
NG - Nigeria 5
AL - Albania 4
BO - Bolivia 4
BZ - Belize 4
GE - Georgia 4
GP - Guadalupe 4
HR - Croazia 4
Totale 46.876
Salva come PNG Salva come JPEG
Città #
Ashburn 3.107
Southend 2.220
Fairfield 2.118
Santa Clara 1.946
Singapore 1.634
Woodbridge 1.451
Chandler 1.119
Houston 1.034
Hong Kong 997
San Jose 962
Seattle 950
Jacksonville 944
Hefei 858
Wilmington 821
Ann Arbor 788
Dearborn 752
Cambridge 746
Council Bluffs 687
Chicago 660
Nyköping 559
Los Angeles 505
Beijing 448
London 408
Ho Chi Minh City 324
Salt Lake City 266
The Dalles 264
Helsinki 261
Hanoi 248
Seoul 246
Modena 235
New York 218
San Diego 209
Princeton 208
Izmir 207
Milan 195
Dallas 178
Buffalo 174
Sofia 170
Eugene 166
Frankfurt am Main 145
Lauterbourg 136
Bremen 125
Moscow 124
Shanghai 110
Elk Grove Village 103
São Paulo 100
Redwood City 98
Tampa 93
Rome 89
Columbus 83
Orem 83
Phoenix 78
Tokyo 71
Des Moines 69
Bologna 66
Washington 64
Lancaster 60
Dublin 57
Boardman 56
Munich 56
Sterling 53
Toronto 52
Atlanta 50
Guangzhou 49
Fremont 48
Montreal 48
Da Nang 43
Haiphong 43
Brooklyn 42
Chennai 42
Miami 42
Verona 41
Denver 40
Philadelphia 40
Norfolk 38
Nanjing 37
Mexico City 36
Naples 36
Amsterdam 34
Jakarta 34
Parma 32
Brussels 31
Norwalk 31
Detroit 30
Rio de Janeiro 30
San Francisco 29
Pittsburgh 28
Baghdad 27
Jinan 27
Kunming 27
Miano 27
Mumbai 27
Charlotte 26
Napoli 26
Stockholm 25
Warsaw 25
Belo Horizonte 24
Dulles 24
Paris 24
New Delhi 23
Totale 32.540
Salva come PNG Salva come JPEG
Nome #
1-Benzopyran-4-one antioxidants as aldose reductase inhibitors 503
Targeting the Central Nervous System: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123 486
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics 478
7-Hydroxy-2-substituted-4-H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: a SAR study 468
PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid 452
Laboratorio di Preparazione Estrattiva e Sintetica dei Farmaci 450
Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution 443
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections 440
Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures 439
Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution 437
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections 435
The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant 430
Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier 414
Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors 413
2′-Deoxyuridine 5′-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives 405
A rational approach to the design of flavones as xanthine oxidase inhibitors 400
NUOVE MOLECOLE, PER USO COME AGENTI ANTITUMORALI 389
Aldose reductase does catalyse the reduction of glyceraldehyde through a stoichiometric oxidation of NADPH. 388
Challenges in the design of clinically useful brain-targeted drug nanocarriers 387
Polymeric nanoparticles for the drug delivery to the central nervous system 387
Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase 383
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs 380
Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy 376
Synthesis and description of chalcone-like compounds, inhibitors of aldose reductase 375
Privileged structures as leads in medicinal chemistry 374
Development of flavonoids derivatives as leads against Leishmaniasis and Trypanosomiasis-invited lecture 367
Binding of beta-carbolines and related agents at serotonin (5-HT-2 and 5-HT-1A), dopamine (D-2) and benzodiazepine receptors 365
Anti-TB inhalation therapy: Design of mannose-based functionalised Solid Lipid Microparticles for an active targeting to alveolar macrophages 361
New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications 360
A model of the interaction of substrates and inhibitors with xanthine oxidase 359
Synthesis and structure-activity relationships of 1-aralkyl-4- benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent σ ligands 358
ANTIINFLAMMATORY ACTIVITY OF NEWLY SYNTHESIZED 2,6-BIS-(1,1-DIMETHYLETHYL)PHENOL DERIVATIVES 354
Current and Future Chemotherapy for Chagas Disease 354
Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors 350
Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase 348
STAT3 as Target for cancer drug discovery 348
ANTICANCER DRUGS 347
Binding of 1-benzopyran-4-one derivatives to aldose reductase: A free energy perturbation study 345
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To InhibitTrypanosoma bruceiPteridine Reductase in Support of Early-Stage Drug Discovery 343
Is there a clinical future for polymeric nanoparticles as brain targeting drug delivery agents? 342
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds 342
Novel engineered lipid-based nanoparticles for pulmonary tuberculosis inhalation therapy 341
Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles 339
Soft docking and multiple receptor conformations in virtual screening. 336
Colloidal systems for CNS drug delivery 328
Designed multiple ligands: basic research vs clinical outcomes 321
Design, synthesis and biological evaluation of non-covalent AmpC Beta-Lactamases inhibitors 321
Magnetic and Optical Bistability in Tetrairon(III) Single Molecule Magnets Functionalized with Azobenzene Groups 318
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth 317
Applicazione delle tecniche microscopiche, spettroscopiche e calorimetriche nella caratterizzazione di nanoparticelle funzionalizzate 317
Glycopeptide-decorated nanoparticles as drug carriers for CNS: effects of surface coverage and carbohydrate type 314
Structure-based design of an inhibitor modeled at the substrate active site of aldose reductase 313
A series of diarylsubstituted oximes as potential substrates for new aldose reductase inhibitors 313
Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches 312
Synthesis and aldose reductase inhibitory activity of benzoyl-amino acid derivatives 311
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent 308
Synthesis and activity of a new series of chalcones as aldose reductase inhibitors 306
Iron acquisition pathways as targets for antitubercular drugs 304
Small-angle neutron scattering characterization of liposomes for anti-tuberculosis inhaled therapy. 301
Isolation and Pharmacological Activities of the Tecoma stans Alkaloids 298
Structural bases for the inhibition of aldose reductase by phenolic compounds 297
Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders 297
In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment? 297
Folate: Relevance of Chemical and Microbial Production 295
Ghrelin receptor modulators: a patent review (2011-2014) 293
Nitrophenyl derivatives as Aldose Reductase inhibitors 290
Peptide-derivatized biodegradable nanoparticles able to cross the blood brain barrier 289
Cell internalization study of hybrid chitosan-heparin-PLGA nanocarriers on Caco-2 cells 288
Engineered polylactide-co-glycolide(PLGA) Np as drug delivery systems for the Central Nervous System 285
Pharmacological approaches to the treatment of diabetic complications 285
Quantitative measurement of proton dissociation and tautomeric constants of apigeninidin 285
Discovery of new inhibitors of aldose reductase from molecular docking and database screening 285
ANTHOCYANIDINES AS INHIBITORS OF XANTHINE-OXIDASE 283
Synthesis and Aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. 282
Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic? 282
Ghrelin receptor modulators and their therapeutic potential 281
Composition, Superoxide Radicals Scavenging and Antilipoperoxidant Activity of some Edible Fruits 279
SURFACE ENGINEERING OF SOLID LIPID NANOASSEMBLIES FOR INHALED INTRAMACROPHAGIC ANTI-TB THERAPY 279
Physico-chemical properties of anthocyanidins. Part 1. Theoretical evaluation of the stability of the neutral and anionic tautomeric forms 277
Nanoparticelle per il direzionamento cerebrale di farmaci 277
Aerodynamic performance of lipid-based nanocarrier functionalized by novel mannose derivatives for Rifampicin intramacrophagic delivery 275
Attivité antifongique in vitro de l’huille essentielle de chemotypes de lavandin 275
Unusual Targeting of the human Thymidylate synthase interface: a tethering approach with mass-spectrometric detection. 275
Drugs/lamellae interface influences the inner structure of double-loaded liposomes for inhaled anti-TB therapy: An in-depth small-angle neutron scattering investigation 275
Identificazione, caratterizzazione e proprietà biologiche di derivati calconici da GLYCYRRHIZA GLABRA L. 274
COMPOSTI AD ATTIVITÀ ANTIPARASSITARIA 272
Oxidative modification of aldose reductase induced by copper ion. Factors and conditions affecting the process 271
An overview on the potential antimycobacterial agents targeting serine/threonine protein kinases from Mycobacterium tuberculosis 268
Modified PLGA Nanoparticles as drug carriers for CNS delivery 266
Fragment Based Discovery of Thymidylate Synthase Dimeric Interface Inhibitors Through Mass Spectrometry. Invited lecture to the Fragment Based Lead Discovery track. 265
Activité Antilipoperoxydante d'Extraits Polyphenoliques de Ribes Nigrum L. 264
Compounds having antiparasitic activity 263
New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents 262
Nanoparticelle polimeriche per il direzionamento di farmaci al Sistema Nervoso Centrale 261
Synthesis, characterization and aldose reductase inhibitory of chalcone derivatives 261
Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. 261
Solvent effects on the tautomerism of apigeninidin 258
Surface decorated nanoparticles as drug delivery agents to the brain 256
Peptide-decorated nanoparticles as carriers for drug delivery to CNS 255
Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors 255
Totale 33.231
Salva come PNG Salva come JPEG
Categoria #
all - tutte 176.584
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 176.584
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.918 0 0 0 0 79 155 167 206 290 200 487 334
2022/20233.139 417 341 225 281 420 479 73 246 410 54 114 79
2023/20241.868 69 119 105 191 431 178 177 246 57 51 79 165
2024/20256.613 287 86 133 447 1.315 925 450 424 663 416 696 771
2025/202613.336 696 503 1.195 1.752 2.514 981 1.355 641 1.183 970 867 679
2026/20274.016 331 778 1.045 1.505 357 0 0 0 0 0 0 0
Totale 47.178